This report contains market size and forecasts of Receptor Tyrosine Protein Kinase Targeted Drugs in global, including the following market information:
- Global Receptor Tyrosine Protein Kinase Targeted Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Receptor Tyrosine Protein Kinase Targeted Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Receptor Tyrosine Protein Kinase Targeted Drugs companies in 2021 (%)
The global Receptor Tyrosine Protein Kinase Targeted Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Afatinib Dimaleate Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Receptor Tyrosine Protein Kinase Targeted Drugs include Aslan Pharmaceuticals Pte Ltd, Boehringer Ingelheim GmbH, GamaMabs Pharma SA, Hanmi Pharmaceuticals Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Minerva Neurosciences Inc, Pfizer Inc, Puma Biotechnology Inc and Shanghai Fosun Pharmaceutical (Group) Co Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Receptor Tyrosine Protein Kinase Targeted Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Receptor Tyrosine Protein Kinase Targeted Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Receptor Tyrosine Protein Kinase Targeted Drugs Market Segment Percentages, by Type, 2021 (%)
- Afatinib Dimaleate
- Dacomitinib
- Neratinib
- Neucardin
- Others
Global Receptor Tyrosine Protein Kinase Targeted Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Receptor Tyrosine Protein Kinase Targeted Drugs Market Segment Percentages, by Application, 2021 (%)
- Oncology
- Cardiovascular
- Central Nervous System
- Others
Global Receptor Tyrosine Protein Kinase Targeted Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Receptor Tyrosine Protein Kinase Targeted Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Receptor Tyrosine Protein Kinase Targeted Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Receptor Tyrosine Protein Kinase Targeted Drugs revenues share in global market, 2021 (%)
- Key companies Receptor Tyrosine Protein Kinase Targeted Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
- Key companies Receptor Tyrosine Protein Kinase Targeted Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Aslan Pharmaceuticals Pte Ltd
- Boehringer Ingelheim GmbH
- GamaMabs Pharma SA
- Hanmi Pharmaceuticals Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Minerva Neurosciences Inc
- Pfizer Inc
- Puma Biotechnology Inc
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- XuanZhu Pharma Co Ltd
- Zensun (Shanghai) Sci & Tech Co Ltd
